Highlights Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 06:00:00 12/05/26 am AEST			5-day change	1st Jan Change
199.14 ^USD	+2.52%		-5.87%	-13.07%

08/05	Natera, Inc., Q1 2026 Earnings Call, May 07, 2026
08/05	Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours	MT

Highlights

08/05	Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours	MT
08/05	(NTRA) Natera Expects Full Year 2026 Revenue Range $2.74B - $2.82B, vs. FactSet Est of $2.67B	MT
08/05	Earnings Flash (NTRA) Natera Posts Q1 Loss $0.60, vs. FactSet Est of $0.54 Loss	MT
08/05	Earnings Flash (NTRA) Natera, Inc. Reports Q1 Revenue $696.6M, vs. FactSet Est of $617.1M	MT
08/05	Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
22/04	Natera, Inc. Features Prospera Evidence In Heart And Lung Transplantation Across 17 Presentations at ISHLT	CI
09/04	Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales	MT
01/04	Natera Inc Announces Signatera MRD Identifies Breast Cancer Patients Who Can Forgo Surgery	CI
17/03	Natera Inc Highlights Clinical Utility of Signatera in Anal and Rectal Cancers	CI
13/03	Natera Inc Announces Commercial Launch of Zenith Genomics	CI
13/03	Natera and Myome Enter Strategic Alliance for Rare Disease Genomics	CI
28/02	Signatera?? Mrd Data At Asco Gu Highlights Potential Utility Across Gu Cancers, Including for Bladder Preservation	CI
27/02	Natera Q4 Operating Loss Narrows, Revenue Rises	MT
27/02	(NTRA) Natera Expects 2026 Revenue Range $2.62B - $2.70B, vs. FactSet Est. of $2.61B	MT
27/02	Earnings Flash (NTRA) Natera, Inc. Reports Q4 Revenue $665.5M, vs. FactSet Est of $604.0M	MT
27/02	Natera, Inc. Provides Earnings Guidance for the Year 2026	CI
27/02	Natera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/02	Natera, Inc. Announces Results from the Sinergy Trial	CI
07/02	Natera, Inc. Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes	CI
02/02	Natera submits Signatera(TM) CDx PMA to FDA	RE
02/02	Natera, Inc. Submits Signatera CDx PMA to FDA	CI
29/01	Natera Announces Completion of Enrollment in Randomized ACES-EMBTrial in Heart Transplantation	CI
21/01	Natera, Inc. Publishes Clinical Validation of Latitude?? Tissue-Free MRD Test in Colorectal Cancer	CI
14/01	Natera Unveils AI Model to Enhance Cancer Recurrence Risk Assessment	MT
14/01	Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling	CI